doxapram has been researched along with Apnea in 58 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Apnea: A transient absence of spontaneous respiration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants." | 9.41 | Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023) |
| "Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants." | 9.22 | Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial. ( Benard, M; Boutroy, MJ; Casper, C; Greze, E; Haddad, FE; Hamon, I; Hascoët, JM, 2016) |
| "Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator." | 9.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| "Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 9.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| "A blinded, randomized, placebo-controlled trial was conducted to evaluate the effectiveness of theophylline and doxapram therapy in 31 infants with significant apnea of prematurity." | 9.06 | A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. ( Finer, NN; Peliowski, A, 1990) |
| "A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity." | 9.05 | Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study. ( Alpan, G; Arad, I; Dgani, Y; Eyal, F; Glick, B; Peleg, O; Sagi, E, 1985) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 8.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| " The diagnosis of apnea of prematurity (AOP) is one of exclusion." | 8.82 | Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003) |
| " theophylline, aminophylline or caffeine) for the treatment of apnea in preterm infants." | 8.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 8.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| "In preterm infants with recurrent apnea, how does treatment with doxapram compare with treatment with theophylline in leading to a clinically important reduction in apnea and use of mechanical ventilation, without clinically important side effects." | 8.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)." | 7.83 | Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016) |
| " There was a marked difference in the cumulative dosage and duration of doxapram therapy used for apnea of prematurity (total dose 2233 +/- 1927 mg vs 615 +/- 767 mg, P < ." | 7.71 | Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. ( Demianczuk, N; Etches, PC; Robertson, CM; Sreenan, C, 2001) |
| "An approximate 80% reduction in the frequency of apnea was found with only minimal side effects following low-dose doxapram." | 7.71 | Low-dose doxapram therapy for idiopathic apnea of prematurity. ( Fujimura, M; Itahashi, K; Kajiwara, M; Yamazaki, T, 2001) |
| "Continuous monitoring of premature infants with apnea is mandatory in order to define the pathophysiology and the type of apnea, and to assess the efficacy and tolerance of the treatment." | 7.70 | [Treatment of apnea in prematurity]. ( Boutroy, MJ; Hascoët, JM, 1998) |
| "5 mg/kg/h) doxapram may help wean from positive airway pressure very low birthweight (less than or equal to 1250 g) infants with apnea unresponsive to aminophylline." | 7.68 | Low-dose doxapram for apnea unresponsive to aminophylline in very low birthweight infants. ( Brion, LP; Reinersman, G; Roth, P; Vega-Rich, C, 1991) |
| "The ventilatory effects of doxapram in the initial pharmacotherapy for apnea in the newborn were evaluated in 8 premature infants with idiopathic apnea." | 7.68 | Doxapram for the initial treatment of idiopathic apnea of prematurity. ( Bairam, A; Faulon, M; Monin, P; Vert, P, 1992) |
| "We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects." | 7.68 | Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991) |
| "5 mg/kg/h theophylline) were administered in that order and in reverse order to patients with apnea of prematurity." | 7.68 | Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity. ( Coutts, RT; Finer, NN; Jamali, F; Malek, F; Peliowski, A, 1991) |
| "Eighteen infants with idiopathic apnea of prematurity refractory to therapeutic levels of aminophylline were treated with incremental doses of doxapram beginning at 0." | 7.67 | Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, G, 1987) |
| "Pharmacokinetics of doxapram were determined in 13 infants with idiopathic apnea of prematurity uncontrolled by aminophylline and caffeine." | 7.67 | Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ( Beaudry, MA; Bradley, JM; Gramlich, LM; LeGatt, D, 1988) |
| "Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2." | 7.67 | Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986) |
| " The final pharmacokinetic model was as follows: CL = BW / PMA × 0." | 6.80 | Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. ( Irie, T; Irikura, M; Ishitsuka, Y; Kamada, N; Kobaru, Y; Kochiyama, Y; Kondo, Y; Ogawa, Y; Ohno, H; Tomiyasu, M; Uriu, M; Yamazaki, T; Yukawa, E, 2015) |
| "To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants." | 5.41 | Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023) |
| " Other pharmacokinetic indices, although variable, did not exhibit binomial distribution." | 5.27 | Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, GA, 1988) |
| "Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants." | 5.22 | Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial. ( Benard, M; Boutroy, MJ; Casper, C; Greze, E; Haddad, FE; Hamon, I; Hascoët, JM, 2016) |
| "Doxapram is used to treat apnea of prematurity when there is an insufficient response to methylxanthine treatment." | 5.11 | Effect of doxapram on cerebral blood flow velocity in preterm infants. ( Horsch, S; Roll, C, 2004) |
| "Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator." | 5.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| "Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 5.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| "A double-blind controlled study, in two parts, was undertaken to compare the effectiveness of aminophylline and doxapram therapy in idiopathic apnea of prematurity." | 5.05 | Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study. ( Alpan, G; Arad, I; Dgani, Y; Eyal, F; Glick, B; Peleg, O; Sagi, E, 1985) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 4.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| " The diagnosis of apnea of prematurity (AOP) is one of exclusion." | 4.82 | Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 4.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| " theophylline, aminophylline or caffeine) for the treatment of apnea in preterm infants." | 4.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "In preterm infants with recurrent apnea, how does treatment with doxapram compare with treatment with theophylline in leading to a clinically important reduction in apnea and use of mechanical ventilation, without clinically important side effects." | 4.80 | Doxapram versus methylxanthine for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "The cerebral metabolic and circulatory effects of the two main classes of respiratory stimulants used in the apnea of the newborn and premature infant, i." | 4.79 | Effects of respiratory stimulants on cerebral metabolism and blood flow. ( Nehlig, A, 1994) |
| "Apnea of prematurity can persist despite caffeine therapy in preterm infants." | 4.02 | The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age. ( Engbers, AGJ; Flint, RB; Knibbe, CAJ; Koch, BCP; Poets, CF; Reiss, IKM; Simons, SHP; Völler, S, 2021) |
| "Doxapram is a treatment option for severe apnea of prematurity (AOP)." | 3.91 | Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. ( de Jongh, FH; de Waal, CG; Hutten, GJ; Kraaijenga, JV; van Kaam, AH, 2019) |
| "Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)." | 3.83 | Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016) |
| "Methylxanthines and doxapram have been used to stimulate breathing and to prevent apnea in preterm infants." | 3.73 | [Determinants of doxapram utilization: a survey of practice in the French Neonatal and Intensive Care Units]. ( Bénard, M; Boutroy, MJ; Casper, C; Glorieux, I, 2005) |
| "Doxapram is a respiratory stimulant widely used for the treatment of idiopathic apnea of prematurity, although it has been demonstrated that it can induce a transient decrease of cerebral blood flow and that isolated mental delay in infants weighing <1,250 g is associated with the total dosage and duration of doxapram therapy." | 3.73 | Brain hemodynamic effects of doxapram in preterm infants. ( Bertini, G; Dani, C; Filippi, L; Pezzati, M; Pratesi, S; Rubaltelli, FF; Tronchin, M, 2006) |
| "An approximate 80% reduction in the frequency of apnea was found with only minimal side effects following low-dose doxapram." | 3.71 | Low-dose doxapram therapy for idiopathic apnea of prematurity. ( Fujimura, M; Itahashi, K; Kajiwara, M; Yamazaki, T, 2001) |
| " There was a marked difference in the cumulative dosage and duration of doxapram therapy used for apnea of prematurity (total dose 2233 +/- 1927 mg vs 615 +/- 767 mg, P < ." | 3.71 | Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. ( Demianczuk, N; Etches, PC; Robertson, CM; Sreenan, C, 2001) |
| "Continuous monitoring of premature infants with apnea is mandatory in order to define the pathophysiology and the type of apnea, and to assess the efficacy and tolerance of the treatment." | 3.70 | [Treatment of apnea in prematurity]. ( Boutroy, MJ; Hascoët, JM, 1998) |
| "Doxapram, a respiratory stimulant, is used to treat idiopathic apnea of prematurity." | 3.70 | Second-degree atrioventricular heart block after doxapram administration. ( De Villiers, GS; Kalis, NN; Van der Merwe, PL; Walele, A, 1998) |
| "The ventilatory effects of doxapram in the initial pharmacotherapy for apnea in the newborn were evaluated in 8 premature infants with idiopathic apnea." | 3.68 | Doxapram for the initial treatment of idiopathic apnea of prematurity. ( Bairam, A; Faulon, M; Monin, P; Vert, P, 1992) |
| "5 mg/kg/h theophylline) were administered in that order and in reverse order to patients with apnea of prematurity." | 3.68 | Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity. ( Coutts, RT; Finer, NN; Jamali, F; Malek, F; Peliowski, A, 1991) |
| "Doxapram was administered orally to six premature babies (3 males, 3 females) with refractory apnea at a mean gestational age of 29 +/- 2." | 3.68 | Gastrointestinal absorption of doxapram in neonates. ( Akramoff-Gershan, L; Aranda, JV; Bairam, A; Beharry, K; Laudignon, N; Papageorgiou, A, 1991) |
| "We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects." | 3.68 | Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. ( Cates, DB; Hasan, SU; Kwiatkowski, K; Rigatto, H; Seifert, B; Tay-Uyboco, J, 1991) |
| "5 mg/kg/h) doxapram may help wean from positive airway pressure very low birthweight (less than or equal to 1250 g) infants with apnea unresponsive to aminophylline." | 3.68 | Low-dose doxapram for apnea unresponsive to aminophylline in very low birthweight infants. ( Brion, LP; Reinersman, G; Roth, P; Vega-Rich, C, 1991) |
| "Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2." | 3.67 | Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986) |
| "Eighteen infants with idiopathic apnea of prematurity refractory to therapeutic levels of aminophylline were treated with incremental doses of doxapram beginning at 0." | 3.67 | Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, G, 1987) |
| "Pharmacokinetics of doxapram were determined in 13 infants with idiopathic apnea of prematurity uncontrolled by aminophylline and caffeine." | 3.67 | Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ( Beaudry, MA; Bradley, JM; Gramlich, LM; LeGatt, D, 1988) |
| "Doxapram (2 mg/kg) was tested on 14 occasions in animals which had developed apnoea during chemical restraint." | 2.68 | Use of the respiratory stimulant doxapram in southern elephant seals (Mirounga leonina). ( Burton, HR; McLean, S; Nicol, S; Slip, DJ; Woods, R, 1996) |
| "Doxapram treatment influences aEEG in preterm infants, showing higher percentages of continuous activity as well as more electrographic seizure activity and less sleep-wake cycling." | 1.40 | Amplitude-integrated electroencephalography shows that doxapram influences the brain activity of preterm infants. ( Berger, A; Czaba-Hnizdo, C; Klebermass-Schrehof, K; Olischar, M; Rona, Z; Weninger, M, 2014) |
| "Doxapram-treated infants were significantly younger and had a lower birth weight." | 1.39 | Doxapram and hypokalaemia in very preterm infants. ( Ferdynus, C; Fischer, C; Gouyon, JB; Semama, DS, 2013) |
| "Doxapram infusion was given to five preterm infants in whom therapeutic concentrations of theophylline had failed to control episodes of apnoea." | 1.27 | Idiopathic apnoea of prematurity treated with doxapram and aminophylline. ( Alpan, G; Arad, I; Eyal, F; Patz, D; Sagi, E, 1984) |
| " Other pharmacokinetic indices, although variable, did not exhibit binomial distribution." | 1.27 | Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. ( Barrington, KJ; Coutts, RT; Finer, NN; Jamali, F; Torok-Both, GA, 1988) |
| " At the moment, xanthines are the drugs of choice, since they are both effective and safe, provided dosage is adjusted to each patient." | 1.26 | [Drug treatment of apnoea in premature infants (author's transl)]. ( Klethi, J; Mack, G; Messer, J; Willard, D, 1981) |
| "Doxapram was detected by mass spectrometry for blood and plasma assays, and by flame ionisation for urine assays." | 1.26 | Quantitation of doxapram in blood, plasma and urine. ( Moore, RG; Nichol, H; Thomas, J; Vine, J, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (32.76) | 18.7374 |
| 1990's | 15 (25.86) | 18.2507 |
| 2000's | 14 (24.14) | 29.6817 |
| 2010's | 8 (13.79) | 24.3611 |
| 2020's | 2 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, S | 1 |
| Avdic, E | 1 |
| Pessano, S | 1 |
| Fiander, M | 1 |
| Soll, R | 1 |
| Bruschettini, M | 1 |
| Engbers, AGJ | 1 |
| Völler, S | 1 |
| Poets, CF | 2 |
| Knibbe, CAJ | 1 |
| Reiss, IKM | 1 |
| Koch, BCP | 1 |
| Flint, RB | 1 |
| Simons, SHP | 1 |
| de Waal, CG | 1 |
| Hutten, GJ | 1 |
| Kraaijenga, JV | 1 |
| de Jongh, FH | 1 |
| van Kaam, AH | 3 |
| Fischer, C | 1 |
| Ferdynus, C | 1 |
| Gouyon, JB | 1 |
| Semama, DS | 1 |
| Czaba-Hnizdo, C | 1 |
| Olischar, M | 1 |
| Rona, Z | 1 |
| Weninger, M | 1 |
| Berger, A | 1 |
| Klebermass-Schrehof, K | 1 |
| Ogawa, Y | 1 |
| Irikura, M | 1 |
| Kobaru, Y | 1 |
| Tomiyasu, M | 1 |
| Kochiyama, Y | 1 |
| Uriu, M | 1 |
| Ishitsuka, Y | 1 |
| Kondo, Y | 1 |
| Yukawa, E | 1 |
| Kamada, N | 1 |
| Ohno, H | 1 |
| Yamazaki, T | 2 |
| Irie, T | 1 |
| Ten Hove, CH | 2 |
| Vliegenthart, RJ | 2 |
| Te Pas, AB | 1 |
| Brouwer, E | 1 |
| Rijken, M | 1 |
| van Wassenaer-Leemhuis, AG | 1 |
| Onland, W | 2 |
| Greze, E | 1 |
| Benard, M | 2 |
| Hamon, I | 2 |
| Casper, C | 2 |
| Haddad, FE | 1 |
| Boutroy, MJ | 4 |
| Hascoët, JM | 3 |
| Flint, R | 1 |
| Halbmeijer, N | 1 |
| Meesters, N | 1 |
| van Rosmalen, J | 1 |
| Reiss, I | 1 |
| van Dijk, M | 1 |
| Simons, S | 1 |
| Bhatt-Mehta, V | 1 |
| Schumacher, RE | 1 |
| Roll, C | 1 |
| Horsch, S | 1 |
| Henderson-Smart, D | 1 |
| Steer, P | 3 |
| Marlier, L | 1 |
| Gaugler, C | 1 |
| Messer, J | 2 |
| Glorieux, I | 1 |
| Dani, C | 1 |
| Bertini, G | 1 |
| Pezzati, M | 1 |
| Pratesi, S | 1 |
| Filippi, L | 1 |
| Tronchin, M | 1 |
| Rubaltelli, FF | 1 |
| Willard, D | 1 |
| Mack, G | 1 |
| Klethi, J | 1 |
| Sagi, E | 3 |
| Eyal, F | 3 |
| Alpan, G | 3 |
| Patz, D | 2 |
| Arad, I | 2 |
| Dear, PR | 1 |
| Wheeler, D | 1 |
| Springer, C | 1 |
| Goder, K | 1 |
| Nichol, H | 1 |
| Vine, J | 1 |
| Thomas, J | 1 |
| Moore, RG | 1 |
| Nehlig, A | 1 |
| Sun, KO | 1 |
| Woods, R | 1 |
| McLean, S | 1 |
| Nicol, S | 1 |
| Slip, DJ | 1 |
| Burton, HR | 1 |
| De Villiers, GS | 1 |
| Walele, A | 1 |
| Van der Merwe, PL | 1 |
| Kalis, NN | 1 |
| Huon, C | 1 |
| Rey, E | 1 |
| Mussat, P | 1 |
| Parat, S | 1 |
| Moriette, G | 1 |
| Darraj, S | 1 |
| Bohnhorst, B | 1 |
| Henderson-Smart, DJ | 4 |
| Steer, PA | 2 |
| Bhatia, J | 1 |
| Kajiwara, M | 1 |
| Itahashi, K | 1 |
| Fujimura, M | 1 |
| Sreenan, C | 1 |
| Etches, PC | 1 |
| Demianczuk, N | 1 |
| Robertson, CM | 1 |
| Bairam, A | 3 |
| Faulon, M | 1 |
| Monin, P | 1 |
| Vert, P | 2 |
| Brion, LP | 1 |
| Vega-Rich, C | 1 |
| Reinersman, G | 1 |
| Roth, P | 1 |
| Merchant, RH | 1 |
| Irani, AJ | 1 |
| Jamali, F | 3 |
| Coutts, RT | 3 |
| Malek, F | 1 |
| Finer, NN | 5 |
| Peliowski, A | 2 |
| Ruggins, NR | 1 |
| Akramoff-Gershan, L | 1 |
| Beharry, K | 1 |
| Laudignon, N | 1 |
| Papageorgiou, A | 1 |
| Aranda, JV | 1 |
| Tay-Uyboco, J | 1 |
| Kwiatkowski, K | 1 |
| Cates, DB | 1 |
| Seifert, B | 1 |
| Hasan, SU | 1 |
| Rigatto, H | 1 |
| Barrington, KJ | 3 |
| Peters, KL | 1 |
| Barton, J | 1 |
| Torok-Both, G | 1 |
| Clyburn, PA | 1 |
| Rosen, M | 1 |
| Torok-Both, GA | 1 |
| Beaudry, MA | 1 |
| Bradley, JM | 1 |
| Gramlich, LM | 1 |
| LeGatt, D | 1 |
| Rose, SJ | 1 |
| Lloyd, DJ | 1 |
| Duffty, P | 1 |
| Hayakawa, F | 1 |
| Hakamada, S | 1 |
| Kuno, K | 1 |
| Nakashima, T | 1 |
| Miyachi, Y | 1 |
| Cater, G | 1 |
| Shaffer, S | 1 |
| Hall, RT | 1 |
| Glick, B | 1 |
| Peleg, O | 1 |
| Dgani, Y | 1 |
| Zocche, GP | 1 |
| Musto, P | 1 |
| Orecchia, C | 1 |
| Stovner, J | 1 |
| Plaut, MR | 1 |
| Gifford, RR | 1 |
| Jacobsen, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Dosing Chart Taking Into Account Age and Gender for Calculating the First Dose of Doxapram in Premature Infants[NCT00389909] | Phase 4 | 85 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for doxapram and Apnea
| Article | Year |
|---|---|
Doxapram for the prevention and treatment of apnea in preterm infants.
Topics: Aminophylline; Apnea; Caffeine; Doxapram; Humans; Infant, Newborn; Infant, Premature; Lung Diseases | 2023 |
Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
Topics: Apnea; Caffeine; Doxapram; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infa | 2017 |
Treatment of apnea of prematurity.
Topics: Aminophylline; Apnea; Caffeine; Clinical Trials as Topic; Doxapram; Humans; Infant, Newborn; Infant, | 2003 |
Doxapram treatment for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2004 |
Effects of respiratory stimulants on cerebral metabolism and blood flow.
Topics: Adult; Animals; Animals, Newborn; Apnea; Brain; Cerebrovascular Circulation; Doxapram; Energy Metabo | 1994 |
Doxapram treatment for apnea in preterm infants.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Respirator | 2000 |
Doxapram versus methylxanthine for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2000 |
Current options in the management of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Prema | 2000 |
Doxapram versus methylxanthine for apnea in preterm infants.
Topics: Aminophylline; Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2000 |
Risks and benefits of therapies for apnoea in premature infants.
Topics: Apnea; Doxapram; Feeding Methods; Humans; Infant, Newborn; Infant, Premature; Positive-Pressure Resp | 2000 |
Doxapram treatment for apnea in preterm infants.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Respirator | 2001 |
Pharmacotherapy of neonatal apnea.
Topics: Apnea; Caffeine; Citrates; Doxapram; Drug Combinations; Humans; Infant, Newborn; Theophylline | 1991 |
Pathophysiology of apnoea in preterm infants.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Larynx; Pharynx; Positive-Pre | 1991 |
10 trials available for doxapram and Apnea
| Article | Year |
|---|---|
Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.
Topics: Apnea; Asian People; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cytoch | 2015 |
Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial.
Topics: Apnea; Double-Blind Method; Doxapram; Female; Humans; Infant; Infant, Newborn; Infant, Premature; In | 2016 |
Effect of doxapram on cerebral blood flow velocity in preterm infants.
Topics: Anterior Cerebral Artery; Apnea; Blood Flow Velocity; Cerebrovascular Circulation; Doxapram; Female; | 2004 |
Olfactory stimulation prevents apnea in premature newborns.
Topics: Apnea; Aromatherapy; Bradycardia; Caffeine; Central Nervous System Stimulants; Combined Modality The | 2005 |
Use of the respiratory stimulant doxapram in southern elephant seals (Mirounga leonina).
Topics: Animals; Apnea; Doxapram; Drug Administration Routes; Female; Intubation; Respiratory System Agents; | 1996 |
Low-dose doxapram for treatment of apnoea following early weaning in very low birthweight infants: a randomized, double-blind study.
Topics: Apnea; Blood Pressure; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Doxapram; H | 1998 |
Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants.
Topics: Apnea; Birth Weight; Bradycardia; Caffeine; Doxapram; Drug Resistance; Gestational Age; Humans; Hypo | 1999 |
A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity.
Topics: Apnea; Doxapram; Drug Combinations; Female; Humans; Infant, Newborn; Infant, Premature; Infusions, I | 1990 |
Patient-controlled analgesia with a mixture of pethidine and doxapram hydrochloride. A comparison of the incidence of respiratory dysrhythmias with pethidine alone.
Topics: Adult; Aged; Apnea; Carbon Dioxide; Doxapram; Drug Therapy, Combination; Female; Humans; Male; Meper | 1988 |
Aminophylline versus doxapram in idiopathic apnea of prematurity: a double-blind controlled study.
Topics: Aminophylline; Apnea; Double-Blind Method; Doxapram; Drug Resistance; Drug Therapy, Combination; Hum | 1985 |
35 other studies available for doxapram and Apnea
| Article | Year |
|---|---|
The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age.
Topics: Apnea; Caffeine; Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2021 |
Doxapram Treatment and Diaphragmatic Activity in Preterm Infants.
Topics: Apnea; Birth Weight; Diaphragm; Doxapram; Electromyography; Female; Gestational Age; Humans; Infant, | 2019 |
Doxapram and hypokalaemia in very preterm infants.
Topics: Analysis of Variance; Apnea; Diuretics; Doxapram; Female; Furosemide; Humans; Hypokalemia; Infant, E | 2013 |
Amplitude-integrated electroencephalography shows that doxapram influences the brain activity of preterm infants.
Topics: Apnea; Brain; Doxapram; Electroencephalography; Female; Gestational Age; Humans; Infant, Newborn; In | 2014 |
Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Central Nervous System Stimulants; Child Development; Doxapram; D | 2016 |
Retrospective study shows that doxapram therapy avoided the need for endotracheal intubation in most premature neonates.
Topics: Apnea; Doxapram; Female; Humans; Infant, Newborn; Infant, Premature; Intubation, Intratracheal; Male | 2017 |
[Determinants of doxapram utilization: a survey of practice in the French Neonatal and Intensive Care Units].
Topics: Apnea; Doxapram; France; Health Care Surveys; Humans; Infant, Newborn; Infant, Newborn, Diseases; In | 2005 |
Brain hemodynamic effects of doxapram in preterm infants.
Topics: Apnea; Birth Weight; Blood Flow Velocity; Brain; Case-Control Studies; Doxapram; Gestational Age; Hu | 2006 |
[Drug treatment of apnoea in premature infants (author's transl)].
Topics: Apnea; Chemoreceptor Cells; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Neurotra | 1981 |
Idiopathic apnoea of prematurity treated with doxapram and aminophylline.
Topics: Aminophylline; Apnea; Carbon Dioxide; Doxapram; Drug Therapy, Combination; Female; Humans; Infant, N | 1984 |
Doxapram and neonatal apnoea.
Topics: Apnea; Doxapram; Dyskinesia, Drug-Induced; Humans; Infant, Newborn | 1984 |
Doxapram in the treatment of idiopathic apnea of prematurity unresponsive to aminophylline.
Topics: Aminophylline; Apnea; Doxapram; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Premature, Dise | 1984 |
Quantitation of doxapram in blood, plasma and urine.
Topics: Apnea; Doxapram; Flame Ionization; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Infant, | 1980 |
Doxapram in tubeless anaesthesia for microlaryngeal surgery.
Topics: Anesthesia, Intravenous; Apnea; Doxapram; Humans; Intraoperative Complications; Intubation; Intubati | 1993 |
Second-degree atrioventricular heart block after doxapram administration.
Topics: Apnea; Doxapram; Female; Heart Block; Humans; Hyaline Membrane Disease; Infant, Newborn; Infant, Pre | 1998 |
[Treatment of apnea in prematurity].
Topics: Apnea; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Premature; Infa | 1998 |
Low-dose doxapram therapy for idiopathic apnea of prematurity.
Topics: Apnea; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature; Infant, Prem | 2001 |
Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea.
Topics: Apnea; Case-Control Studies; Cerebral Hemorrhage; Child Development; Developmental Disabilities; Dox | 2001 |
Doxapram for the initial treatment of idiopathic apnea of prematurity.
Topics: Apnea; Doxapram; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Respiration; To | 1992 |
Low-dose doxapram for apnea unresponsive to aminophylline in very low birthweight infants.
Topics: Aminophylline; Apnea; Benzyl Alcohol; Benzyl Alcohols; Dose-Response Relationship, Drug; Doxapram; D | 1991 |
Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity.
Topics: Apnea; Body Weight; Doxapram; Drug Interactions; Female; Gestational Age; Half-Life; Humans; Infant, | 1991 |
Gastrointestinal absorption of doxapram in neonates.
Topics: Administration, Oral; Apnea; Blood Pressure; Dose-Response Relationship, Drug; Doxapram; Female; Hum | 1991 |
Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant, Ne | 1991 |
Low-dose doxapram for apnoea of prematurity.
Topics: Apnea; Caffeine; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature, Di | 1986 |
Physiologic effects of doxapram in idiopathic apnea of prematurity.
Topics: Aminophylline; Apnea; Birth Weight; Blood Pressure; Carbon Dioxide; Doxapram; Gestational Age; Human | 1986 |
Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity.
Topics: Apnea; Blood Pressure; Carbon Dioxide; Dose-Response Relationship, Drug; Doxapram; Half-Life; Heart | 1987 |
Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data.
Topics: Apnea; Doxapram; Drug Administration Schedule; Humans; Infant, Newborn; Infant, Premature, Diseases | 1988 |
Pharmacokinetics of doxapram in idiopathic apnea of prematurity.
Topics: Apnea; Doxapram; Female; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases | 1988 |
Doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases | 1987 |
Doxapram in the treatment of idiopathic apnea of prematurity: desirable dosage and serum concentrations.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, Parenteral | 1986 |
Doxapram for apnea of prematurity.
Topics: Apnea; Doxapram; Humans; Infant, Newborn; Infant, Premature, Diseases | 1986 |
A new analeptic agent: doxapram hydrochloride (Dopram).
Topics: Apnea; Central Nervous System Stimulants; Doxapram; Humans; Postoperative Complications | 1966 |
[Considerations on the use of a new respiratory analeptic, doxapram (3,3-diphenyl-1-ethyl-4-(alpha-morpholinoethyl)-2-pyrrolidone chlorydrate) in the differential diagnosis and treatment of post-narcotic apnea].
Topics: Adult; Aged; Anesthesia; Apnea; Central Nervous System Stimulants; Doxapram; Humans; Middle Aged; Mo | 1967 |
[Doxapram. A respiration stimulator].
Topics: Apnea; Central Nervous System Stimulants; Doxapram; Humans; Morpholines; Postoperative Care; Pyrroli | 1969 |
Recovery from central respiratory failure and administration of doxapram to a patient with a brainstem lesion.
Topics: Apnea; Brain Stem; Cerebrovascular Disorders; Coma; Doxapram; Female; Humans; Middle Aged; Quadriple | 1973 |